The latest news, stories and exciting findings from across the Oxford cancer research community
Oxford ranked first in the world for Computer Science
22 October 2021
For the fourth year running the University of Oxford has been ranked first in the world for Computer Science in the 2022 World University Rankings. Many Oxford Cancer members are working in computer science to develop AI algorithms to detect cancer earlier, and implement machine learning into new technologies.
Pancreatic cancer early detection funds awarded to Oxford researchers
19 October 2021
Dr Pui San Tan and Professor Julia Hippisley-Cox receive a Research Innovation Award from Pancreatic Cancer UK to develop a risk tool to predict pancreatic cancer in patients with diabetes.
Applied mathematical principles help identify immune cell spatial patterns in tumours
15 October 2021
A collaboration between mathematicians, pathologists and clinicians has shown how techniques from computational algebraic topology can be used to understand the spatial distributions of immune cell subtypes within tumours.
Six new Fellowships announced as part of Oxford-Bristol Myers Squibb Fellowships Programme
14 October 2021
The Oxford - Bristol Myers Squibb (BMS) Fellowships Programme continued to demonstrate significant progress over the last year. Six new Oxford fellowships were announced, including two significant cancer projects.
Oxford cancer clinical trials unit receives acclaimed nursing award
13 October 2021
The nursing team at the Early Phase Clinical Trials Unit has been awarded the Excellence in Cancer Research Nursing Award 2021.
Haematology workshops enable significant patient involvement
7 October 2021
The 'What Matters Most’ initiative was designed as a way of bringing people with Myelodyspastic Syndrome together to talk about their shared experience, and agree a list of priorities for research and service / resource development.
Anti-cancer drug derived from fungus shows promise in clinical trials
6 October 2021
A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.
Blood tests may predict response to immunotherapy for melanoma
4 October 2021
A study from the Fairfax lab provides new insight into the factors that determine patient response to Immune Checkpoint Blockers, a common immunotherapy treatment for melanoma.
Turing Fellowships for Oxford cancer researchers
1 October 2021
Oxford Cancer community members will join the Turing network for 2021-2022 to further their research in cancer big data.
New atlas revealed of bone marrow haematopoiesis during development
1 October 2021
A new study published this week in Nature, provides the most detailed analysis so far of the prenatal development of blood and immune cells in the bone marrow.
FOCUS4: a flagship trial in colorectal cancer
20 September 2021
Professor Tim Maughan outlines the flagship work of the FOCUS4 trials, whose results were presented this weekend at the European Society of Medical Oncology (ESMO) annual meeting
Changing drinking patterns in China could drive a major increase in liver diseases
19 September 2021
According to new research led by NDPH, Chinese people who regularly drink alcohol have significantly greater risks of developing severe liver diseases, such as cancer.
New drug shows promise in slowing growth of bowel cancer
18 September 2021
The latest results from the multi-arm FOCUS4 trial, led by Tim Maughan at the University of Oxford, has shown that the drug adavosertib has promising activity in bowel cancer patients
Changes in blood cell production over the human lifetime may hold clues to patterns of disease
16 September 2021
A new paper published this week in Cell Reports reveals that changes in the gene expression of blood stem cells occur across the human lifetime; an important step in the understanding and treatment of blood cancers.
Oxford to assess revolutionary multi-cancer blood test in trial, for future implementation in the NHS
15 September 2021
A partnership between the University of Oxford and GRAIL, LLC will evaluate the use of a new, non-invasive, multi-cancer early detection test known as Galleri in suspected cancer patients.
Oxford Cancer Analytics awarded £1.27M to revolutonise lung cancer management
10 September 2021
OXcan, an Oxford University spin out, has raised money to apply their machine learning approach to lung cancer early detection
Vaccine for treating cancer made possible using Oxford COVID vaccine technology
3 September 2021
A new publication from Benoit Van den Eynde's group has shown that a viral vector cancer vaccine generates effective anti-tumour immune responses and, in combination with immunotherapy, decreases tumour size and increases survival rates in mouse models.
Oxford’s cancer-risk research featured in special edition of PLOS Medicine focussed on advances in early cancer detection
2 September 2021
Research from Dr Brian Nicholson and colleagues outlines how routine clinical tests could be widely used to estimate the risk of cancer for people visiting their GPs with unexpected weight loss.
World Chronic Lymphoid Leukaemia Day 2021
1 September 2021
Researchers from Oxford University and OUH are joining celebrations for the first world CLL day on 1 September 2021.
Two Oxford immunotherapy research projects awarded funding by Prostate Cancer UK
31 August 2021
Prostate Cancer UK have invested £1.7 million into five immunotherapy projects, including two from Profs Kate Vallis, Richard Bryant and Eileen Parkes at the University of Oxford. Read about their funded work.